News and updates with the latest clinical trials, medical reports and interesting developments within the DMD community.
A boy has been dosed on the Sarepta EMBARK gene therapy clinical trial for Duchenne muscular dystrophy (DMD) at the John Walton Muscular Dystrophy Research Centre, a world-leading neuromuscular research centre run by Newcastle University and Newcastle Hospitals.
A boy has been dosed on the Sarepta EMBARK gene therapy clinical trial for Duchenne muscular dystrophy (DMD) at the John Walton Muscular Dystrophy Research Centre, a world-leading neuromuscular research centre run by Newcastle University and Newcastle Hospitals.
The John Walton Muscular Dystrophy Research Centre (Newcastle University) and Duchenne UK are delighted to announce that the DMD Hub Central Recruitment Pilot Project is now active and accepting registrations.
Register online at: www.dmdhubrecruits.org
Read about the impact of the DMD Hub in 2021 in our latest impact report.
On Thursday 31st March 2022, 7-8pm, Dr Michela Guglieri (Consultant Neurologist at Newcastle University and Newcastle Hospitals NHS Foundation Trust) and Dr Anne-Marie Childs (Consultant Paediatric Neurologist, Leeds Teaching Hospitals NHS Trust) will be hosting a webinar (for patients/families) to discuss the launch of the DMD Hub Central Recruitment Pilot Project.
In the last few months, the DMD Hub has recruited two new staff members to work with Emma Heslop, the DMD Hub Manager, and to look at new areas where the DMD Hub can develop support.
The DMD Hub is one of Duchenne UK’s flagship projects and has successfully expanded capacity for Duchenne muscular dystrophy (DMD) clinical trials in the UK. By funding key posts at hospital sites across the UK, many more boys are now able to take part in trials for potentially life-changing treatments.
We were delighted to welcome the following new staff to the DMD Hub network. Each team member will play an important role in running effective trials for potential DMD treatments:
A team of researchers and clinicians from Sheffield Hallam University, Sheffield Children’s NHS Foundation Trust and Leeds Teaching NHS Trust are developing an immersive virtual reality (VR) platform to help children living with Duchenne muscular dystrophy (DMD) engage in physiotherapy exercises.
Pfizer has announced that the first UK-based DMD patient has been enrolled in a gene therapy trial at Newcastle Hospitals NHS Foundation, a DMD Hub site.
This week we were delighted to have been featured in a publication from the National Institute for Health Research (NIHR), who have highlighted the DMD Hub, as an example of how they work alongside industry to support clinical trials.
Gene Therapy is a promising new treatment for DMD and the DMD Hub is committed to making the recruitment process to these trials as clear as possible for the patient community